Paris France /
Two doses of the Pfizer / BioNTech vaccine are effective in preventing the risk of hospitalization from COVID-19 and all its variants for at least six months, according to a study published Tuesday in The Lancet.
The study by Pfizer and the American health network Kaiser Permanente analyzed the medical data of 3.4 million people in the southern state of California between December 4 and August 8.
Dconcluded that the effectiveness of the vaccine against the risks of infection decreases over time, going from 88 percent in the month following the second dose, to 44 percent after six months.
Secondly, the vaccine maintains its 90 percent efficacy against the risks of hospitalization by covid-19, including delta variant infection, for at least six months, the study revealed.
The data confirm the results of previous estimates from the US Centers for Disease Control and Prevention. (CDC), the main federal public health agency in the United States, and Israel’s Ministry of Health, The Lancet said in a statement.
“Our study confirms that vaccines are a central tool in controlling the epidemic and are extremely effective in preventing severe forms and hospitalizations, including against delta and other worrisome variants,” Sara Tartof, lead author of the study, summarized in the statement.
Luis Jodar, vice president and chief medical officer of Pfizer, said that “a specific analysis of the variants clearly shows that the vaccine is effective against all types of variants.”
GIVES
–
– .
